– In preclinical studies, CHS-1000 shows high affinity for human ILT4 and reverses ILT4-mediated immunosuppressive function, leading to immune cell activation and increased cytokine secretion. –
– Mechanisms by which immunotherapy may enhance antitumor responses –
– First novel immuno-oncology product candidate discovered and developed by Coherus –
– CHS-1000 IND submission expected in Q2 2024 –
REDWOOD CITY, Calif., April 8, 2024 (Globe Newswire) — CoHealth Bioscience Co., Ltd. Coherus (Nasdaq: CHRS) today announced preclinical data for its novel ILT4 monoclonal antibody CHS-1000, an immuno-oncology pipeline candidate, at the 2024 AACR Annual Meeting in San Diego, California. The data presented demonstrate that CHS-1000 is a potent monoclonal antibody that selectively binds human ILT4 (also known as LILRB2) with high affinity and effectively blocks interaction with its ligand. It has been shown to reverse immunosuppressive function, leading to activation of human dendritic cells and T cells. Polarization of macrophages toward an inflammatory M1 phenotype.
“Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major cause of tumor immune infiltration and PD-1 resistance. The data presented in this poster demonstrate that CHS-1000 reverses myelosuppression and stimulates the inflammatory immune response. Reprogramming myeloid cells in the tumor microenvironment is a novel immunotherapeutic approach aimed at overcoming resistance to IO therapy and potentially benefiting more cancer patients. ,” said Dr. Teresa Lavallee, chief development officer at CoHealth. “CHS-1000 is our first development candidate discovered internally and we are excited to be able to file an IND this quarter. We plan to introduce it clinically in both cases.®”
These data will be presented at today's poster session, and posters will be available for download at the time of the presentation.
Summary: 1364/15
Title: Characterization of Fc-modified anti-ILT4 monoclonal antibody CHS-1000 to reprogram suppressive myeloid cells in solid tumors
Speaker: Dr. Narendhiran Rajasekharan
Session PO.IM01.02 – Immune checkpoints and inhibitory molecules 1
Date and Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM PDT
Poster data is summarized as follows:
- CHS-1000 specifically and selectively bound human ILT4 (LILRB2) with high affinity and showed no cross-reactivity to other LILRB family members.
- CHS-1000 efficiently blocks the interaction of ILT4 with its ligands HLA-A and HLA-G, reverses ILT4-mediated immunosuppressive function, and inhibits the activation of M1 macrophages, dendritic cells, and T cells. oxidation and increased secretion of proinflammatory cytokines.in in vitro Assay.
- CHS-1000 is Fc-silent and lacks effector function activity. in vitro Assays consistent with engineered modifications of the Fc region of antibodies. Human FcRn transgenic mice also have IgG1-like PK parameters.
- ILT4 and CD163, a marker for inhibitory (M2) macrophages, are highly expressed in a wide range of solid tumors.
About CHS-1000
Discovered and developed by Coherus, CHS-1000 is a novel humanized Fc-modified IgG1 monoclonal antibody that specifically targets ILT4 (LILRB2). CHS-1000 is designed to overcome myeloid cell-mediated immunosuppression and resistance in the tumor microenvironment. In preclinical studies, CHS-1000 promotes repolarization of suppressive M2 macrophages to a pro-inflammatory M1 phenotype and enhances dendritic cell and T cell activation in vitro. CoHealth plans to file an investigational new drug (IND) application in the second quarter of 2024 and begin clinical studies later this year.
About CoHealth Bioscience
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies for the treatment of cancer. CoHealth is developing an innovative immuno-oncology pipeline that is synergistic with proven commercial capabilities in oncology.
CoHealth's immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing innate and adaptive immune responses, enabling robust immune responses and improving outcomes for cancer patients Let me do it. Casdozokitug is a novel anti-IL drug currently being evaluated in his two ongoing clinical studies: an ongoing Phase 1/2 trial in solid tumors and a Phase 2 trial in hepatocellular carcinoma. 27 antibodies. CHS-114 is a highly selective and competitively positioned ADCC-enhancing anti-CCR8 antibody currently in Phase 1/2 trials as monotherapy in patients with advanced solid tumors . CHS-1000 is a preclinical candidate targeting immunosuppressive mechanisms through the novel pathway ILT4, with an IND filing expected in Q2 2024.
CoHealth brings Roktorji to market® (tripalimab-tpzi), a novel next-generation PD-1 inhibitor UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®Yushimuri® (adalimumab-aqvh), biosimilar to Humira®.
New Rasta® is a registered trademark of Amgen.
humira® is a registered trademark of AbbVie Inc.
Forward-looking statements
Except for historical information contained herein, the matters contained in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements that: including but not limited to. Coherus' ability to identify synergies between his IO pipeline and commercial capabilities. The expected timing of CoHealth's IND filing for CHS-1000. CoHealth expects to be able to advance candidates through clinical trials. And Coherus hopes its immunotherapy candidates will improve outcomes for cancer patients.
Such forward-looking statements may contain material risks that could cause CoHealth's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. It involves risks and uncertainties. Such risks and uncertainties include those inherent in the preclinical and clinical drug development process. risks associated with Coherus' existing and potential collaboration partners; risks to Coherus' competitive position; risks and uncertainties in the regulatory approval process, including the speed of regulatory reviews and the timing of Coherus' regulatory filings; risk of FDA review issues; Competition Risk. the risk that Coherus will be unable to complete commercial transactions; risks and uncertainties arising from potential litigation; All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For more information about important risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements and risks associated with CoHealth's business generally, please contact CoHealth on Form 10-K. See our annual report. For the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 15, 2024, the section entitled “Risk Factors” and other filings made by Coherus with the Securities and Exchange Commission. Contains documents.
Udenica®Yushimuri®Loktorzi®is a trademark of Coherus, its affiliates, affiliates, or its licensors or joint venture partners, whether or not shown in large print or with the trademark symbol, unless otherwise noted. Trademarks and trade names of other companies mentioned in this press release are, to the best of Coherus's knowledge, the property of their respective owners.
CoHealth contact information:
For investors:
jamie taylor
Head of Investor Relations
IR@coherus.com
For media:
Jody Seavers
Vice President of Corporate Communications
media@coherus.com